PMID- 31043990
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1734-9338 (Print)
IS  - 1897-4295 (Electronic)
IS  - 1734-9338 (Linking)
VI  - 15
IP  - 1
DP  - 2019
TI  - Safety of bivalirudin versus unfractionated heparin in endovascular 
      revascularization of peripheral arteries in short- and long-term follow-up.
PG  - 91-97
LID - 10.5114/aic.2019.81757 [doi]
AB  - INTRODUCTION: Patients with peripheral artery disease (PAD) are considered as a 
      high-risk group for hemorrhagic events. AIM: To assess the safety of bivalirudin 
      vs. unfractionated heparin (UFH) in percutaneous peripheral interventions (PPI) 
      in short- and long-term follow-up. MATERIAL AND METHODS: The retrospective 
      single-center, observational study included 160 patients, undergoing PPI. 
      Patients were divided into 2 groups based on the use of anticoagulation - 
      unfractionated heparin (UFH group) or bivalirudin (Biv. group) - and observed up 
      to 5 years. RESULTS: The UFH group consisted of 101 patients and the Biv. group 
      consisted of 59. We registered the following end points during in-hospital 
      observation: 1 death (0.63% Biv, p = 0.18), 12 hematomas at puncture site (0.63% 
      Biv. vs. 7.05% UFH, p = 0.04), 2 pseudoaneurysms (1.27% UFH, p = 0.29), 
      thrombosis (0.63% UFH, p = 0.45), 1 bleeding from puncture site (0.63% UFH, p = 
      0.45). The total number of hemorrhagic complications was 1.24% in the Biv. group 
      and 8.07% in the UFH group (p = 0.04). During long-term follow-up of 65.7 +/-36.4 
      months the all-cause mortality rate was higher in the Biv. group (8.59% Biv vs. 
      0% in UFH group, p = 0.009). Regression analysis showed that bivalirudin 
      administration is a risk factor for increased mortality risk (p = 0.003, OR = 15, 
      95% CI: 3.3-107.8). CONCLUSIONS: Usage of UFH was associated with a higher number 
      of hemorrhagic complications, especially hematomas at the puncture site in 
      comparison to patients receiving bivalirudin.
FAU - Wojtasik-Bakalarz, Joanna
AU  - Wojtasik-Bakalarz J
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Kleczynski, Pawel
AU  - Kleczynski P
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Zasada, Wojciech
AU  - Zasada W
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Rakowski, Tomasz
AU  - Rakowski T
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Arif, Salech
AU  - Arif S
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Bartus, Krzysztof
AU  - Bartus K
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Dudek, Dariusz
AU  - Dudek D
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
FAU - Bartus, Stanislaw
AU  - Bartus S
AD  - 2 Department of Cardiology, Jagiellonian University Medical College, Krakow, 
      Poland.
LA  - eng
PT  - Journal Article
DEP - 20190130
PL  - Poland
TA  - Postepy Kardiol Interwencyjnej
JT  - Postepy w kardiologii interwencyjnej = Advances in interventional cardiology
JID - 101272671
PMC - PMC6488834
OTO - NOTNLM
OT  - bivalirudin
OT  - heparin
OT  - long-term mortality
OT  - peripheral artery disease
COIS- The authors declare no conflict of interest.
EDAT- 2019/05/03 06:00
MHDA- 2019/05/03 06:01
PMCR- 2019/01/01
CRDT- 2019/05/03 06:00
PHST- 2018/05/27 00:00 [received]
PHST- 2018/11/04 00:00 [accepted]
PHST- 2019/05/03 06:00 [entrez]
PHST- 2019/05/03 06:00 [pubmed]
PHST- 2019/05/03 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 34960 [pii]
AID - 10.5114/aic.2019.81757 [doi]
PST - ppublish
SO  - Postepy Kardiol Interwencyjnej. 2019;15(1):91-97. doi: 10.5114/aic.2019.81757. 
      Epub 2019 Jan 30.